Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The retina-specific chaperone aryl hydrocarbon interacting protein-like 1 (AIPL1) is essential for the correct assembly of
phosphodiesterase
6 (PDE6), which is a pivotal effector enzyme for phototransduction and vision because it hydrolyzes cGMP. AIPL1 interacts with the cytokine-inducible ubiquitin-like modifier
FAT10
, which gets covalently conjugated to hundreds of proteins and targets its conjugation substrates for proteasomal degradation, but whether
FAT10
affects PDE6 function or turnover is unknown. Here, we show that
FAT10
mRNA is expressed in human retina and identify rod PDE6 as a retina-specific substrate of
FAT10
conjugation. We found that AIPL1 stabilizes the
FAT10
monomer and the PDE6-
FAT10
conjugate. Additionally, we elucidated the functional consequences of PDE6 FAT10ylation. On the one hand, we demonstrate that
FAT10
targets PDE6 for proteasomal degradation by formation of a covalent isopeptide linkage. On the other hand,
FAT10
inhibits PDE6 cGMP hydrolyzing activity by noncovalently interacting with the PDE6 GAFa and catalytic domains. Therefore,
FAT10
may contribute to loss of PDE6 and, as a consequence, degeneration of retinal cells in eye diseases linked to inflammation and inherited blindness-causing mutations in AIPL1.
...
PMID:The ubiquitin-like modifier FAT10 inhibits retinal PDE6 activity and mediates its proteasomal degradation. 3281 38